Bhat, Raksha
Thangavel, Hariprasad
Abdulkareem, Noor Mazin
Vasaikar, Suhas
De Angelis, Carmine
Bae, Leon
Cataldo, Maria Letizia
Nanda, Sarmistha
Fu, Xiaoyong
Zhang, Bing
Schiff, Rachel
Trivedi, Meghana V.
Funding for this research was provided by:
Department of Defense BCRP (W81XWH-14-1-0341, W81XWH-14-1-0340)
Breast Cancer Research Foundation (BCRF-18-145, BCRF-19-145)
NIH (CA125123, P50 CA058183, CA186784-01)
Article History
Received: 15 September 2021
Accepted: 13 January 2022
First Online: 4 February 2022
Competing interests
: Rachel Schiff receives/has received research funding from AstraZeneca, GlaxoSmithKline, Puma, Biotechnology Inc., and Gilead Sciences (to the institution); she has been a past ad hoc advisory committee member for Eli Lilly; she is a consulting/advisory committee member for Macrogenics; and she has other financial interests: UpToDate Royalties. Carmine De Angelis has served as consultant/advisory board member for Eli Lilly, GSK, Novartis, Pfizer. Carmine De Angelis has received research support from Novartis. All other authors declare no conflict of interest.